On Invalid Date, Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q4 2023 earnings per share (EPS) of -$0.18, up 0% year over year. Total Adaptimmune Therapeutics earnings for the quarter were -$47.92 million. In the same quarter last year, Adaptimmune Therapeutics's earnings per share (EPS) was -$0.18.
As of Q2 2024, Adaptimmune Therapeutics's earnings has grown year over year. Adaptimmune Therapeutics's earnings in the past year totalled -$113.87 million.
What is ADAP's earnings date?
Adaptimmune Therapeutics's earnings date is Invalid Date. Add ADAP to your watchlist to be reminded of ADAP's next earnings announcement.
What was ADAP's revenue last quarter?
On Invalid Date, Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q4 2023 revenue of $231.00 thousand up 97.91% year over year. In the same quarter last year, Adaptimmune Therapeutics's revenue was $11.03 million.
What was ADAP's revenue growth in the past year?
As of Q2 2024, Adaptimmune Therapeutics's revenue has grown 122.05% year over year. This is 26.36 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Adaptimmune Therapeutics's revenue in the past year totalled $60.28 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.